What type of study is this?

This is a In Vitro Study study.

August 21, 2025Open Access

Figure 6 from Direct Co-Targeting of Bcl-xL and Mcl-1 Exhibits Synergistic Effects in AR-V7–Expressing CRPC Models

Key Points

Synergistic effects were observed when using both bcl-xl and mcl-1 inhibitors in CRPC models, enhancing antitumor activity.
Cell viability tests showed significant improvement with dual treatment in LNCaP95 and VCaP-CR cell lines, with P < 0.01.
Analysis included 2D and 3D spheroid models, confirming the effectiveness of the drug combination in various formats.
These findings suggest innovative approaches for treating CRPC, highlighting the need for further studies on combination therapies.

Abstract

XZ739 in combination with S63845 has synergistic antitumor effects in CRPC cell lines. A to I, CellTiter-Glo viability data from 2D cultures of LNCaP95, VCaP-CR, and 22Rv1 cell lines. Cell viability data for the dual treatment (A–C) were generated by CellTiter-Glo. Dose–response matrices (D–F) and Bliss synergy plots (G–I) were created using the SynergyFinder+ R package. J to M, 3D spheroid model and cell viability of LNCaP95 (J and K) and 22Rv1 cells (L and M). Data are presented as mean ± SD. **, P P

Figure 6 from Direct Co-Targeting of Bcl-xL and Mcl-1 Exhibits Synergistic Effects in AR-V7–Expressing CRPC Models

Key Points

Abstract

Cite This Study